220 related articles for article (PubMed ID: 15150548)
1. Is there a role for chemotherapy in prostate cancer?
Canil CM; Tannock IF
Br J Cancer; 2004 Sep; 91(6):1005-11. PubMed ID: 15150548
[TBL] [Abstract][Full Text] [Related]
2. Current chemotherapeutic approaches for androgen-independent prostate cancer.
Rumohr JA; Chang SS
Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Berry WR
Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
[TBL] [Abstract][Full Text] [Related]
4. [Prostate cancer and chemotherapy].
Gravis G; Salem N; Bladou F; Viens P
Bull Cancer; 2007 Jul; 94(7 Suppl):F21-8. PubMed ID: 17845990
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
[TBL] [Abstract][Full Text] [Related]
6. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
[TBL] [Abstract][Full Text] [Related]
7. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
8. [Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
Ferrero JM
Bull Cancer; 2005 May; 92(5):425-7. PubMed ID: 15932803
[TBL] [Abstract][Full Text] [Related]
9. Which drug combination for hormone-refractory prostate cancer?
Doggrell SA
Expert Opin Pharmacother; 2005 Apr; 6(4):667-70. PubMed ID: 15934892
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy for prostate cancer].
Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
[TBL] [Abstract][Full Text] [Related]
11. Update in the management of patients with hormone-refractory prostate cancer.
Moore CN; George DJ
Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy for prostate cancer].
Itoh N
Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
[TBL] [Abstract][Full Text] [Related]
13. Future directions in the treatment of androgen-independent prostate cancer.
Petrylak DP
Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
15. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
16. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
17. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
Collins R; Fenwick E; Trowman R; Perard R; Norman G; Light K; Birtle A; Palmer S; Riemsma R
Health Technol Assess; 2007 Jan; 11(2):iii-iv, xv-xviii, 1-179. PubMed ID: 17181985
[TBL] [Abstract][Full Text] [Related]
18. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Burgess EF; Roth BJ
Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in prostate cancer.
Small EJ
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
[TBL] [Abstract][Full Text] [Related]
20. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
